HOME ·

R&D Progress

TRANSTHERA-B (02617.HK): Tinengotinib Included in CSCO Guidelines for Biliary Tract Malignancies (2026)
Tags：
TRANSTHERA-B02617.HKR&D Progress
2026-09-18
IMPACT THERAP-B (07630.HK): Sepalna Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Ovarian Cancer
Tags：
IMPACT THERAP-B07630.HKR&D Progress
2026-09-18
SHANDONG XINHUA (00719.HK): Obtains Drug Registration Certificate for Levocarnitine Oral Solution
Tags：
SHANDONG XINHUA00719.HKR&D Progress
2026-09-18
HAIXI PHARMA (02637.HK): HX9428 Phase I and Phase II nAMD data show continued BCVA improvement
Tags：
HAIXI PHARMA02637.HKR&D Progress
2026-09-16
CSPC PHARMA (01093.HK): Phase II Trial of SYH2069 Injection for Adult Type 2 Diabetes Commences at First Site in China
Tags：
CSPC PHARMA01093.HKR&D Progress
2026-09-16
SSY GROUP (02005.HK): Ziprasidone Mesylate Approved for Registration as API for Use in Marketed Formulations
Tags：
SSY Group02005.HKR&D Progress
2026-09-16
BASECARE-B (02170.HK): Gems vitrification freezing and thawing solution kits obtain Class III medical device registration certificates
Tags：
BASECARE-B02170.HKR&D Progress
2026-09-15
CSPC PHARMA (01093.HK): SYS6010 Included in China's Breakthrough Therapy Designation List for Driver-Gene-Negative Non-Squamous NSCLC
Tags：
CSPC PHARMA01093.HKR&D Progress
2026-09-15
BOAN BIOTECH (06955.HK): Masked PD-1/IL-2 Prodrug BA1203 Approved for Clinical Trial in China for Multiple Solid Tumours
Tags：
BOAN BIOTECH06955.HKR&D Progress
2026-09-14
HENGRUI PHARMA (01276.HK): Marketing Application for Class 1 Innovative Drug SHR-2004 Injection Accepted by NMPA for VTE Prevention After Knee Replacement Surgery
Tags：
HENGRUI PHARMA01276.HKR&D Progress
2026-09-14
CMS (00867.HK): Innovative Drug CMS-D001, a Highly Selective TYK2 Inhibitor, Receives Drug Clinical Trial Approval Notice for Systemic Lupus Erythematosus Indication
Tags：
CMS00867.HKR&D Progress
2026-09-14
CSPC PHARMA (01093.HK): Phase I/II Data of SYS6010 Combined with Enlangsuba Monoclonal Antibody in Previously Untreated Driver-Gene-Negative Advanced NSCLC Presented as Oral Presentation at 2026 WCLC
Tags：
CSPC PHARMA01093.HKR&D Progress
2026-09-14
LEADS BIOLABS-B (09887.HK): Updated Phase II Data of Vilxin® Combined with Chemotherapy as First-Line Treatment for NSCLC Presented in Oral Presentation at WCLC 2026
Tags：
LEADS BIOLABS-B09887.HKR&D Progress
2026-09-14
PEIJIA-B (09996.HK): NMPA Approval for Registration Application of GeminiOne® Transcatheter Edge-to-Edge Repair System
Tags：
PEIJIA-B09996.HKR&D Progress
2026-09-11
HENGRUI PHARMA (01276.HK): HER3 ADC Ruzaltatug Rezetecan granted breakthrough therapy designation
Tags：
HENGRUI PHARMA01276.HKR&D Progress
2026-09-11
FOSUN PHARMA (02196.HK): Registration application for new specification of HLX14 denosumab biosimilar accepted by NMPA
Tags：
FOSUN PHARMA02196.HKR&D Progress
2026-09-11
HANSOH PHARMA (03692.HK): Small Cell Lung Cancer Product HS-20093 Included in NMPA Priority Review Procedure
Tags：
HANSOH PHARMA03692.HKR&D Progress
2026-09-11
OCUMENSION-B (01477.HK): NDA for OT-301 in Open-Angle Glaucoma or Ocular Hypertension Accepted by NMPA
Tags：
OCUMENSION-B01477.HKR&D Progress
2026-09-11
HENGRUI PHARMA (01276.HK): Hetrombopag Olamine Tablets approved for two additional indications, becoming world's first TPO-RA approved for CTIT
Tags：
HENGRUI PHARMA01276.HKR&D Progress
2026-09-10
SSY GROUP (02005.HK): Wins NMPA approval for Letermovir Injection, deemed to have passed consistency evaluation
Tags：
SSY Group02005.HKR&D Progress
2026-09-10
1234